Abstract
Despite decades long clinical usage, aminoglycosides still remain a valuable pharmaceutical source for fighting Gram-negative bacterial pathogens, and their newly identified bioactivities are also renewing interest in this old class of antibiotics. As Nature's gift, some aminoglycosides possess natural defensive structural elements that can circumvent drug resistance mechanisms. Thus, a detailed understanding of aminoglycoside biosynthesis will enable us to apply Nature's biosynthetic strategy towards expanding structural diversity in order to produce novel and more robust aminoglycoside analogs. The engineered biosynthesis of novel aminoglycosides is required not only to develop effective therapeutics against the emerging ‘superbugs’ but also to reinvigorate antibiotic lead discovery in readiness for the emerging post-antibiotic era.
Original language | English |
---|---|
Pages (from-to) | 33-41 |
Number of pages | 9 |
Journal | Current Opinion in Biotechnology |
Volume | 48 |
DOIs | |
Publication status | Published - 2017 Dec 1 |
Bibliographical note
Funding Information:We thank Dr Kris Rathwell for critically reading this manuscript. This work was supported by the National Research Foundation of Korea grants (2016R1A2A1A05005078, 2015R1A2A2A01002524 [J.W.P.]) funded by the Ministry of Science, ICT and Future Planning (MISP), and the Intelligent Synthetic Biology Center of the Global Frontier Project funded by MISP (20110031961), Advanced Production Technology Development Program (114048-03-3-CG000) and High Value-added Food Technology Development Program (114019-05-3-HD020), Ministry of Agriculture, Food and Rural Affairs, Republic of Korea. J.W.P. also thanks the Next-Generation BioGreen21 program, Rural Development Administration for its grant (PJ011066).
Publisher Copyright:
© 2017 Elsevier Ltd
ASJC Scopus subject areas
- Biotechnology
- Bioengineering
- Biomedical Engineering